Archive for the ‘Gene Therapy Research’ Category

The Global Cancer Therapies Market analysis report published on Dataintelo.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=94024

The Global Cancer Therapies Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Cancer Therapies Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Cancer Therapies Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=94024

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Cancer Therapies Market as:Global Cancer Therapies Market Size & Share, by Regions

Global Cancer Therapies Market Size & Share, by ProductsImmunological and Vaccine ApproachesAntiproliferative ApproachesPhotodynamic TherapyGene Therapy ApproachesCell Cycle and Apoptosis Approaches

Global Cancer Therapies Market Size & Share, ApplicationsHospital UseClinic UseHouseholdOther

Key PlayersAmgenAstraZenecaBristol-Myers SquibbBayer AGF. Hoffmann-La Roche LtdGlaxoSmithKline PLCJohnson & JohnsonMerck & Co. Inc.Novartis AGPfizer Inc.

Avail the Discount on this Report @ https://dataintelo.com/ask-for-discount/?reportId=94024

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

More:
Global Cancer Therapies Market 2026 Size, Key Companies, Trends, Growth And Regional Forecasts Research - Cole of Duty

A Research study on High Intensity Focused Ultrasound Therapy Market analyzes and offers ideas of exhaustive research on ancient and recent High Intensity Focused Ultrasound Therapy market size. Along with the estimated future possibilities of the market and emerging trends in the High Intensity Focused Ultrasound Therapy market.

The global high-intensity focused ultrasound therapy market is expected to reach US$ 417.98 Mn in 2018 and is predicted to grow at a CAGR of 7.1% during the forecast period 2019 2027, to reach US$ 755.46 Mn by 2027.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/7739

Therapeutic ultrasound segment held a largest market share of the High-Intensity Focused Ultrasound therapy market. This segment is also expected to dominate the market in 2027 because it increases the healing rates, tissue relaxation, and its heating, local blood flow, and scar tissue breakdown. Moreover, others segment is expected to grow at significant rate, in the forecast period 2019 to 2027 because lithotripsy, thrombolysis, immunomodulation, and among others medical procedures are increasing.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/7739

The market for high-intensity focused ultrasound therapy is expected to grow, owing to factors such as growing cancer prevalence across the globe, rising incidences of kidney stone and prostate diseases, rising preference for non-invasive procedures. In addition, growing hospital industry in developing nations are likely to have a positive impact on the growth of the market in the coming years.

What will you get in this report?

Genetic testing helps evaluate the chance of developing cancer in a lifetime. The genetic testing is done by searching for specific mutations in genes, chromosomes, or proteins. An inherited gene mutation causes hereditary cancer. An inherited gene is the one which is passed from parent to child in a family. Various methods are used for hereditary cancer testing; it includes genetic counseling. The counseling provides a discussion regarding recommendations for preventive care and screening with the patient. They support groups and other information resources and provide emotional support to the person getting the results.

Global high-intensity focused ultrasound therapy market is segmented by modality, method, application, and end user. On the basis of modality, the market is segmented into Therapeutic Ultrasound, Hemostasis, Others. On the basis of method, the market is segmented into Non-Invasive and Minimal-Invasive. On the basis of Application, the market is segmented into Uterine Fibroids, Prostate Cancer, Others. Based on end user, the market is segmented into Hospitals, Research Centers, and Diagnostic Centers. In 2018, the imaging held the largest share in the market, by diagnosis type.

Some of the major primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), Centers for Medicare & Medicaid Services (CMS), Cancer Organisation Soutien (CDS), National Institute of Cancer Prevention and Research (NICPR), National Cancer Institute, Canadian Institutes of Health Research (CIHR), Spanish Society of Medical Oncology (SEOM), and others.

A Pin-point overview of TOC of High Intensity Focused Ultrasound Therapy Market are:

Overview and Scope of High Intensity Focused Ultrasound Therapy Market

High Intensity Focused Ultrasound Therapy Market Insights

Industry analysis - Porter's Five Force

Company Profiles

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/7739

Go here to see the original:
High Intensity Focused Ultrasound Therapy Market Sales, Price, Revenue, Gross Margin and Share 2027 - CueReport

The report on Global Gene Therapy Partnering Terms and Agreements 2014 to 2020 is suitably segmented and sub-segmented so that it can shade light on every aspect of market such as type of product, application, and region. On the basis of recent developments and past data, the report prophesies future revenue, growth, and trend of the Gene Therapy Partnering Terms and Agreements Market landscape. This information is represented in curves, tables, margins, pie charts. Additionally, it emphasizes on faster growing segments and emerging trends in the market. The report provides an in-depth insight into the global Gene Therapy Partnering Terms and Agreements Market covering all important parameters that cover Market Challenge, Driver, Trend and Forecast.

Key Companies Involved in This Report: Company A

Get Free Sample PDF Of Gene Therapy Partnering Terms and Agreements Market @https://www.researchmoz.us/enquiry.php?type=S&repid2696112

Scope of Gene Therapy Partnering Terms and Agreements Market: The report forecast global Gene Therapy Partnering Terms and Agreements market to grow to reach xx Million USD in 2020 with a CAGR of xx% during the period 2020-2026. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values are estimated based on manufacturers revenue. Estimates of the regional markets for Gene Therapy Partnering Terms and Agreements are based on the applications market.

As per the research and study, the market has settled its presence worldwide. Gene Therapy Partnering Terms and Agreements Market Research study offers a comprehensive evaluation of the Market and comprises a future trend, current growth factors, focused opinions, details, and industry certified market data.

Gene Therapy Partnering Terms and Agreements Market Report Answers Important Questions which include

Gene Therapy Partnering Terms and Agreements Market Report Answers Important Questions which include:

End-use Industry Assessment

The report segments the Gene Therapy Partnering Terms and Agreements Market on the basis of end-use industry and offers a detailed understanding of the supply-demand ratio and consumption pattern of the Gene Therapy Partnering Terms and Agreements in each end-use industry.On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, Gene Therapy Partnering Terms and Agreements market share and growth rate of Gene Therapy Partnering Terms and Agreements foreach application, including-

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, Gene Therapy Partnering Terms and Agreements market share and growth rate ofeach type, primarily split into-

Gene Therapy Partnering Terms and Agreements Market Regional analysis includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2696112

Research Objectives and Purpose:

1. To inquire and examine the Gene Therapy Partnering Terms and Agreements market size by important regions/countries, product type and application, past data from 2014 to 2018, and estimate or forecast to 2026.2. To know the structure of Gene Therapy Partnering Terms and Agreements Market by recognizing its several sub-segments.3. To focused on a key Gene Therapy Partnering Terms and Agreements market players, to determine, describe and analyze the value, market share, market competition landscape, SWOT analysis, and development plans in the next few years.4. To interpret the Gene Therapy Partnering Terms and Agreements market concerning specific growth trends, prospects, and their contribution to the total market.5. To share detailed information about the key factors impacting the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).6. To project the size of Gene Therapy Partnering Terms and Agreements Market, concerning key regions, type, and applications.7. To explain competitive developments such as expansions, agreements, new product launches and acquisitions in the market and much more.

For More Information Kindly Contact: ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Media Release @ https://www.researchmoz.us/pressreleaseFollow me on Blogger: https://trendingrelease.blogspot.com/

Read the original here:
Gene Therapy Partnering Terms and Agreements Market 2020 Global Analysis, Growth Opportunities, Top Key Players - Owned

Global Thalassemia Treatment Market Research Report Cover Covid-19 Impact

The Thalassemia Treatment market research report fabricated by Brand Essence Market Research is an in-depth analysis of the latest trends persuading the business outlook. The report also offers a concise summary of statistics, market valuation, and profit forecast, along with elucidating paradigms of the evolving competitive environment and business strategies enforced by the behemoths of this industry.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Sample

Global Thalassemia Treatment Market 2018-2024Brandessence Market Research is working on a new report titleGlobal Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.22.2. Average 18.5%14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Thalassemia Treatment Market report helps to identify opportunities in market place.Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Thalassemia Treatment Market Segmentation

Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood TransfusionChelating TherapyBone Marrow TransplantStem Cell TransplantSurgeryGene TherapyOtherGlobal Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal TestingPrenatal TestingPre-ImplantationOtherGlobal Thalassemia Treatment Market: By End user Analysis

HospitalsBiotechnological LaboratoriesDiagnostic LaboratoriesEducational Research InstitutesPharmaceutical IndustriesOtherGlobal Thalassemia Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and Africa

Request Customization of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Customization

Key Reasons to Purchase:

To gain insightful analyses of the market and a comprehensive understanding of the impact of COVID-19 is likely to have on the Drones Market during the forecast period between 2020 and 2026, and its commercial landscapeTo learn about the market strategies that are being adopted by your competitors and other leading companiesTo understand the future outlook and prospects of the Drones Market post COVID-19To keep you abreast with the strategies used by other players in theTo understand the changes in rules and regulations in various countries during COVID-19 and its possible effects on the market in the future.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/bioanalytical-testing-services-market-is-expected-to-garner-usd-561-billion-by-the-end-of-2025-by-registering-a-cagr-of-987-2020-06-17?tesla=y

https://www.marketwatch.com/press-release/at-402-cagr-cellulosic-ethanol-market-size-set-to-register-440120-million-usd-by-2025-2020-06-17?tesla=y

https://www.marketwatch.com/press-release/software-testing-market-size-share-application-analysis-testing-type-regional-outlook-growth-trends-key-players-and-industry-overview-to-2025-2020-06-17?tesla=y

https://www.marketwatch.com/press-release/global-cleaning-robot-market-2020-key-players-data-industry-analysis-segmentation-share-size-opportunities-and-forecast-to-2025-2020-06-16?tesla=y

https://www.marketwatch.com/press-release/global-guidewires-market-2020-top-countries-data-global-analysis-market-size-business-strategies-geography-trends-and-forecast-2025-2020-06-16?tesla=y

More here:
2020 Growth: Thalassemia Treatment Market 2020 Industry Research, Segmentation, Key Players Analysis and Forecast to 2025 - Cole of Duty

Summary:

Rare diseases comprise a growing public health priority, as they affect upward of 300 million people globally and they are difficult to diagnose and treat.

There is a pressing need for better ways to detect and diagnose rare diseases, as well as to provide companion diagnostics for therapy guidance, clinical trials enrollment and therapy monitoring applications.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4747004

Better diagnostic tests for rare diseases can make significant differences in the lives of those affected by these conditions. Many rare diseases go undiagnosed for long periods of time because patients, families and physicians may have limited awareness of certain diseases, and the symptoms may not be informative to healthcare workers who may not have encountered such diseases before.

An extended time to diagnosis of a rare disease, along with so-called diagnostic odysseys, can lead to negative outcomes, including misdiagnosis or disease progression. Rapid, accurate diagnostics can significantly shorten these diagnostic odysseys.

In addition to early detection and diagnostic potential, rare disease therapeutics will be important in orphan drug development and use. Orphan drugs address rare disease patient populations, and they are expected to have a high growth rate through 2024. By 2024, orphan drugs may make up as much as onefifth of global prescription sales. Rare disease diagnostics can be used to help physicians make proper decisions regarding which therapies to use and ways to monitor the efficacy of those therapies during treatment courses. Rare disease diagnostics can also be used to help select patients for orphan drug clinical trials.

More than 70% of rare diseases are inher+N13ited conditions, and they thus have genetic components, so this industry relies heavily on genetic analysis methods, including polymerase chain reaction (PCR), nextgeneration sequencing (NGS) and Sanger sequencing.

Report Scope:

The scope of the report includes rare disease diagnostic technologies, applications, industries, initiatives, patents and companies. The market for rare disease diagnostic products and services is given for 2018 and 2019, and then forecast through 2024.

Browse the complete report @ https://www.orbisresearch.com/reports/index/rare-disease-diagnostics-technologies-and-global-markets

This report reviews the main diagnostic technologies and explains why genetic variation is important in clinical testing and disease. It then discusses significant large-scale research initiatives that impact rare disease diagnostic applications. Of particular interest is a discussion of global population-scale sequencing projects and their likely impact in linking genetic variation to rare disease diagnostics. The main market driving forces for rare disease diagnostic products and services are listed and discussed.

The report categorizes and quantifies the rare disease diagnostics market by the disease category, technology platform, test purpose, analysis target and geography segments.

Disease categories include cardiovascular; central nervous system; endocrine and metabolic; immune and inflammation; musculoskeletal; ophthalmology; rare cancers; respiratory; and other (gastro-intestinal, Genito-urinary, dermatology and lymphatic categories.

Technology platforms include: mass spectrometry, microarrays, next-generation sequencing (NGS), PCR, Sanger sequencing and other (e.g., karyotyping, fluorescent in situ hybridization).

Test purposes include: screening and early detection, diagnosis, therapy guidance and monitoring.

Analysis targets include single gene, multi-gene panels, whole exome, whole genome, other genomic variants and proteins.

Geographical regions include the Asia-Pacific region, Europe, North America and the Rest of the World (ROW).

Industry sectors influencing rare disease diagnostics discussed in the report include next-generation sequencing, long-read sequencing, PCR, RNA therapies, gene-editing therapies, gene therapies, and genetically modified cell therapies.

More than 95 companies in the rare disease diagnostic industry are profiled in this report.

BCC Research also provides a summary of more than 50 of the main industry acquisitions and strategic alliances that took place from April 2018 through April 2020, including key alliance trends.

Report Includes:

53 tables An overview of the global markets and technologies for rare disease diagnostics and discussion on market opportunities for these technologies Analyses of global market trends with data from 2018, 2019 and projections of compound annual growth rates (CAGRs) through 2024 Evaluation of current market size, market forecast and description of market driving forces Detailed market share analysis and quantification of rare disease diagnostics markets by disease class, indication, analysis platform, analysis target, test purpose and region Briefing about rare disease therapies and how they influence the use of rare disease diagnostics Details about Orphan Drug Act and other initiatives for rare diseases Coverage of the key industries associated with developing and marketing rare disease diagnostics, including the DNA sequencing industry, PCR industry, and laboratory services industry A look at the key industry acquisitions and strategic alliances and discussion on the key partnering trends Profiles of key companies in the rare disease diagnostics industry, including 10x Genomics Inc., Agilent Technologies Inc., Freenome Inc., GenapSys Inc., Illumina Inc., Myriad Genetics Inc. and PerkinElmer Inc.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4747004

Companies Mentioned:10X GENOMICS INC.23ANDME INC.3BILLION INC.ADAPTIVE BIOTECHNOLOGIES INC.ADMERA HEALTHAGILENT TECHNOLOGIES INC.ALCEDIAGAMARANTUS BIOSCIENCE HOLDINGS INC.AMBRY GENETICSARCHIMEDLIFE LABORATORIESARUP LABORATORIESASTRIDBIO TECHNOLOGIES KFT.ASURAGEN INC.ATHENA DIAGNOSTICS INC.BASE4 INNOVATION LTD.BAYLOR GENETICSBC PLATFORMSBERRY GENOMICS CO., LTD.BGI SHENZHENBIO-RAD LABORATORIES INC.BIOCEPT INC.CEGAT GMBHCELLMAX LIFECELSEE DIAGNOSTICSCENTOGENE AGCERGENTIS B.V.DANAHER CORP.DANTE LABSDEVYSER ABDIACARTA INC.DIPLOIDDIRECTED GENOMICS LLCDNANEXUS INC.ELECTRONIC BIOSCIENCESEPIC SCIENCES INC.EUROFINS SCIENTIFICEXPEDEON AGFABRIC GENOMICSFREENOME INC.FULGENT GENETICSFUSION GENOMICS CORP.GENAPSYS INC.GENEDX INC.GENEMIND BIOSCIENCES CO., LTD.GENETICS RESEARCH LLCGENEXOSOME TECHNOLOGIES INC.GENOMATIX SOFTWARE GMBHGENOME PROFILING LLCGENOMENONGENOMIC EXPRESSIONGENOMNIA SRLGENOMONCOLOGYGENOOXGENOSPACEGIGAGEN INC.GOLDEN HELIXGRANDOMICS BIOSCIENCES CO., LTD.GUARDIOMEHELIX OPCO LLCHTG MOLECULAR DIAGNOSTICS INC.ILLUMINA INC.INVITAE INC.KINGMED DIAGNOSTICS CENTER CO., LTD.LABORATORY CORP. OF AMERICA INC.LABORATORY FOR MOLECULAR MEDICINELEUCINE RICH BIO PVT., LTD.LOOP GENOMICSMACROGEN INC.MAYO MEDICAL LABORATORIESMEDGENOME LABS PVT., LTD.MOLECULAR LOOP BIOSOLUTIONS LLCMYRIAD GENETICS INC.NEW ENGLAND BIOLABSNEWGENE LTD.NOSTROS GENOMICSNOVOGENE CO., LTD.OXFORD NANOPORE TECHNOLOGIES LTD.PACIFIC BIOSCIENCES OF CALIFORNIA INC.PERKINELMER INC.PERSONAL GENOME DIAGNOSTICS INC.PREVENTIONGENETICS INC.Q-STATE BIOSCIENCESQUANTAPORE INC.QUANTUM BIOSYSTEMS INC.QUEST DIAGNOSTICS INC.REAL-TIME GENOMICS INC.RETROPHINROCHE HOLDING AGSEVEN BRIDGES GENOMICS INC.SISTEMAS GENOMICOS SLSOFTGENETICS LLCSOPHIA GENETICSSPERA MEDICALSTRAND LIFE SCIENCES PVT., LTD.SUPRATECH MICROPATH LABORATORY & RESEARCH INSTITUTE PVT., LTD.THERMO FISHER SCIENTIFIC INC.TWIST BIOSCIENCE

Original post:
Rare Disease Diagnostics: Technologies and Global Markets Cole Reports - Cole of Duty

LOS ANGELES--(BUSINESS WIRE)--Children's Hospital Los Angeles (CHLA) ranks again among the nations premier destinations for pediatric care, according to the U.S. News & World Report Best Children's Hospitals annual list released today.

CHLA not only retained its national No. 5 ranking in U.S. News Honor Roll of Best Childrens Hospitalswhich recognizes institutions with the most outstanding pediatric clinical careit continued its four-year streak of being the highest-scoring childrens hospital in the entire Western United States.

To make U.S. News & World Reports prestigious Best Childrens Hospitals Honor Roll, one must demonstrate the strongest achievements in clinical excellence, with a matchless team of expert, compassionate specialists committed to research and education as well as protocols that drive safety and quality and consistently lead to the best health outcomes for patients, says CHLA President and Chief Executive Officer Paul S. Viviano. "This honor affirms the work of every CHLA team member and our belief that when parents choose Childrens Hospital Los Angeles, they are choosing the best care for kids."

Every year, U.S. News scores nearly every major hospital and health system in the country and ranks them according to performance benchmarks, peer review, certifications, and other data provided by the hospital and third-party measurements of excellence. Children's hospitals are ranked separately from other facilities due to the specialized expertise, equipment and facilities required to care for infants, children and youth.

This year, U.S. News surveyed 118 pediatric medical centers, including hospitals that are freestanding or part of a larger institution. CHLA improved its ranking over last year in seven of the 10 pediatric specialty categories the survey considers, including a number two ranking for Neonatal Care. In all, the hospital earned top-10 recognition in seven of those categories:

CHLA has an organization-wide commitment to providing our patients the care they need no matter their circumstances, says CHLA Chief Medical Officer James Stein, M.D., MSc. "Our clinical teams often treat the most acute cases that are outside the scope or expertise of other childrens hospitals in California, and being named a Top-5 childrens hospital in the U.S. is a testament to the clinicians and staff who work every day to make sure each child receives the best care and experience possible.

Founded in 1901, Children's Hospital Los Angeles is a pediatric academic medical center built around its mission of creating hope and building healthier futures for children. Renowned for its world-class clinical care, leading-edge research and one of the largest and most successful pediatric training programs in the countryall while being the pediatric safety net hospital for the entire regionCHLA now sees more than 600,000 patient visits annually between its main hospital and five neighborhood care clinics.

CHLA physicians, nurses and clinical staff provide compassionate and lifesaving pediatric care for patients ranging from infants to young adults, hailing from all 50 states and more than 75 countries. Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC. Many of the hospital's achievements in care are made possible through a cohesive relationship between clinical experts at the bedside and the basic, translational, and clinical research conducted in The Saban Research Institute of CHLA.

In the past year, CHLA has had several notable achievements, including:

U.S. News & World Report works with research firm RTI International to develop its annual Best Children's Hospitals list, a collaboration between hospitals and the magazine to benchmark the performance of childrens hospitals for the benefit of parents and their children. The survey evaluates hundreds of data points, including patient survival and surgical complication rates; staffing, technology and special services; infection prevention and delivery of care; reputation among peer physicians nationwide (i.e. Where would the best pediatric specialists send their kids?); how involved parents are in their childrens care; and many other measurements of excellence.

U.S. News Media Group, parent of U.S. News & World Report, announced the 2020-21 hospital rankings online at 12:01 a.m. EDT on Tuesday, June 16. For additional information, please visit the Best Childrens Hospitals Honor Roll and specialty rankings page at usnews.com/childrenshospitals.

About Children's Hospital Los Angeles

Founded in 1901, Children's Hospital Los Angeles is ranked the top childrens hospital in California and fifth in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll of childrens hospitals. Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC through an affiliation dating from 1932. The hospital also leads the largest pediatric residency training program at a freestanding childrens hospital of its kind in the western United States. The Saban Research Institute of Childrens Hospital Los Angeles encompasses basic, translational and clinical research conducted at CHLA. The hospitals Center for Global Health facilitates services for international patients from more than 75 countries. To learn more, follow us on Facebook, Instagram, LinkedIn and Twitter, and visit our blog for families (CHLA.org/blog) and our research blog (ResearCHLABlog.org).

See the original post:
Children's Hospital Los Angeles Ranked No. 1 Children's Hospital in the Western U.S., No. 5 Nationally for Second Straight Year - Business Wire

Cell Culture Media Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

TheCell Culture Media marketreport begins with the market overview/market definition and the market scope. This helps in understanding what exactly is the report study dealing with. The next section includes the target audience of the Cell Culture Media market. It is very important for the clients to understand what type of users or what kind of consumers deal with Cell Culture Media market in order to determine their focus goals.

Request Free Sample Copy of Cell Culture Media Market Research Report@http://www.marketresearchstore.com/report/global-cell-culture-media-market-by-player-region-321243#RequestSample

In the last section, the Cell Culture Media market report incorporates detailed information on the demand & supply chain analysis, import and export, industry size, sales volume, market shares, as well as value analysis of all the industry players operating in the Cell Culture Media market. Some of the major market players that are included areLife Technologies, Corning (Cellgro), Sigma-Aldrich, Thermo Fisher, Merck Millipore, GE Healthcare, Lonza, BD, HiMedia, Takara, CellGenix, Atlanta Biologicals, PromoCell, Zenbio. Each market player is profiles in detail within the report by the research analysts.

In the next section, the Cell Culture Media market report includes the research tools and methodologies that were incorporated while studying the Cell Culture Media market. For instance, Porters Five Force analysis, SWOT analysis, PESTLE analysis, top-down or the bottom-up approach that was used for market data analysis. It also includes details about the primary research and the secondary research that were conducted by the research analysts.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-cell-culture-media-market-by-player-region-321243

The next major section of the Cell Culture Media market study includes the market segmentation. To understand any market with ease the market is segregated into segments, such as its product type, application, technology, end-use industry. By dividing the market into small components helps in understanding the market with more clarity. The market segments of the Cell Culture Media market includes{Classical Media & Salts, Serum-free Media, Stem Cell Media}; {Biopharmaceutical Manufacturing, Tissue Culture & Engineering, Gene Therapy, Cytogenetic}. The data that is provided within the study is both quantitative and qualitative. Data is represented with the help of tables and figures that include graphical representation of the numbers in the form of histograms, bar graphs, pie charts, etc.

Another major segment of the Cell Culture Media market is its geographical presence on the global platform. The major regions that have been considered include Asia Pacific, Europe, Latin America, North America, and the Middle East and Africa. The Cell Culture Media market study is not restricted to regional level but also includes country-wise data.

If Any Inquiry of Cell Culture Media Report:http://www.marketresearchstore.com/report/global-cell-culture-media-market-by-player-region-321243#InquiryForBuying

Major Advantages for Cell Culture Media Market:

Well-organized description of the international Cell Culture Media market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Cell Culture Media industry. The Cell Culture Media market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Cell Culture Media market. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

Go here to read the rest:
Global Cell Culture Media Market 2020 with COVID-19 After Effects Analysis by Top Key Players | Life Technologies, Corning (Cellgro), Sigma-Aldrich,...

The latest Regenerative Medicine Industry market research added by Market Study Report, LLC, delivers a concise outline regarding the potential factors likely to drive the revenue growth of this industry. The report delivers valuable insights on market revenue, SWOT Analysis, market share, profit estimation and regional landscape of this business vertical. Moreover, the report focuses on significant growth factors and obstacles accepted by market leaders in the Regenerative Medicine Industry market.

The Regenerative Medicine Industry market report is an in-depth analysis of this business space. The major trends that defines the Regenerative Medicine Industry market over the analysis timeframe are stated in the report, along with additional pointers such as industry policies and regional industry layout. Also, the report elaborates on the impact of existing market trends on investors.

Request a sample Report of Regenerative Medicine Industry Market at:https://www.marketstudyreport.com/request-a-sample/2727154

COVID-19, the disease it causes, surfaced in late 2020, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

Other information included in the Regenerative Medicine Industry market report is advantages and disadvantages of products offered by different industry players. The report enlists a summary of the competitive scenario as well as a granular assessment of downstream buyers and raw materials.

Revealing a gist of the competitive landscape of Regenerative Medicine Industry market:

Ask for Discount on Regenerative Medicine Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2727154

An outlook of the Regenerative Medicine Industry market regional scope:

Additional takeaways from the Regenerative Medicine Industry market report:

This report considers the below mentioned key questions:

Q.1. What are some of the most favorable, high-growth prospects for the global Regenerative Medicine Industry market?

Q.2. Which products segments will grow at a faster rate throughout the forecast period and why?

Q.3. Which geography will grow at a faster rate and why?

Q.4. What are the major factors impacting market prospects? What are the driving factors, restraints, and challenges in this Regenerative Medicine Industry market?

Q.5. What are the challenges and competitive threats to the market?

Q.6. What are the evolving trends in this Regenerative Medicine Industry market and reasons behind their emergence?

Q.7. What are some of the changing customer demands in the Regenerative Medicine Industry Industry market?

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-regenerative-medicine-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Clinical Pathology Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-clinical-pathology-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global ICAD (Intracranial Atherosclerotic Disease) Pathology Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-icad-intracranial-atherosclerotic-disease-pathology-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

More here:
Regenerative Medicine Market to Witness Growth Acceleration During 2020-2025 - Cole of Duty

For most of us, the immune system works to protect us from bacteria, viruses, and other harmful pathogens.But for people with autoimmune conditions, the body's white blood cells instead perceive other cells and tissues in the body to be a threat and attacks them.

While some immune disorders, like allergies, can sometimes be treated, autoimmune conditions such as multiple sclerosis (MS) remain incurable.

Our research has shown that you can stop the immune system attacking the nerves which is what happens in MS. We did this by giving the immune system ever-increasing doses of the same molecule that the immune system was attacking.

Now we've taken this research one step further to show how this process works inside the white blood cells that make up the immune system.

Our team revealed the complex mechanisms that allow us to switch T cells (a type of white blood cell) from attacking the cells of autoimmune disease patients to protecting them.We learnt how to make reactive T cells tolerant.

Our T cells have evolved so that each one recognises different parts of the molecules made by pathogens (also known as antigens). When the T cells recognise antigens, the T cells start multiplying in order to attack the invaders.

The T cells move from a resting state into a highly activated state by turning on immune response genes that help them attack pathogens.

When an infection is over, some of these T cells remain, giving lifelong immunity as memory T cells. They're able to carry this lifelong memory by imprinting our chromosomes with triggers that allow immune response genes to be reactivated much faster.

In autoimmune diseases such as MS, Graves' disease and type 1 diabetes, the immune system gets it wrong. In MS, the T cells start to see myelin basic protein, a component of the outside, insulating coating that surrounds nerve cells, as an antigen.

They attack the nervous system and, as a result, MS sufferers lose control over their muscles. Our research is trying to rectify this.

To help us understand this process, we focused on the T cells that specifically recognise myelin basic protein as an antigen. We found that over time these T cells became less reactive after they were exposed to gradually increasing doses of the myelin basic protein.

This progressive exposure reprogrammed these T cells so that the signals telling the cells to attack the protein became weaker. This converted the T cells from attacking to protecting.

This switch could be explained by the fact that the immune system is regulated by two types of genes. One type tells the immune system to attack, while the other gene type silences the immune system to stop it going out of control.

We showed that when T cells are made tolerant, two of the most important genes that suppress the immune system were reprogrammed at the level of the chromosome to keep them more active.

Repetitive exposure to the myelin basic protein imprinted a memory within these inhibitory genes. This allowed T cells to remember to inhibit the T cell receptor from sending attack signals when they encountered that same specific myelin basic protein fragment.

The end effect of turning on the inhibitory genes was to weaken the signals inside T cells that would normally turn on other genes that activate the immune system. That meant that the T cells stopped getting the signal telling them to attack nerve cells.

Autoimmune diseases are currently treated using immunosuppressive drugs. The problem with this is that they suppress the whole immune system, making the patient prone to cancers and other infections.

Trials using antigen therapy in patients with MS and Grave's disease are ongoing, but results from short-term preliminary clinical trials showed both MS and Graves' disease patients started to have improved health while the trials lasted.

One day we hope that antigen-based immunotherapy will be able to deliver major benefits for all types of autoimmune disease. By detailing the complex mechanisms that control the fate of self-reactive T cells, we may have also opened the door for more specific therapies for these diseases.

Peter Cockerill, Professor, Institute of Cancer and Genomic Sciences, University of Birmingham and David C. Wraith, Professor of Immunology and Director, Institute of Immunology and Immunotherapy, University of Birmingham, University of Birmingham.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
Autoimmune Experiments Switch Immune Cells From Attacking The Body to Protecting It - ScienceAlert

Cancer Gene Therapy Market size is expected to exceed USD 2.5 billion by 2025. Rising cancer prevalence across the globe will positively impact the cancer gene therapy market growth.Some major findings of the cancer gene therapy market report include:

Increasing mortality rates due to cancer has created a huge demand for cancer gene therapies

Technological advancements in the biotechnology sectors has led to developments in the cancer gene therapy that are being now preferred by healthcare professionals

Regulations for cancer gene therapy are quite structured and stringent in developed economies such as the U.S. and Germany while the regulatory scenario is still ambiguous in emerging economies

Cancer gene therapy industry is still in developing phase and yet to witness numerous growth opportunities in the coming years

Some of the major industry players include: Sirion Biotech, Vigene Biosciences, bluebird bio, Ziopharm, Cellectis, Cobra, Finvector, Uniqure, Sarepta Therapeutics, Caribou among others. These industry players adopt several strategic initiatives to maintain their market position.

Request sample copy of this report @ https://www.gminsights.com/request-sample/detail/763

Technological advancements in the biotechnology sector have led to developments and innovations in cancer gene therapy. Recently developed cancer therapies have been incorporated with genetically modified genes that blocks the growth of tumor. Moreover, efficient PCR technology and isothermal amplification technologies have been introduced that transformed the way of detecting mutations in the genes. Moreover, introduction of CRISPR gene editing tools have modified the process of developing gene therapy. Hence, advancements in technology has ensured availability of advanced cancer gene therapy that will boost the industry growth. However, high cost of cancer gene therapy may impede its demand, thereby restraining the industry growth to certain extent.

Type segment of cancer gene therapy market includes ex-vivo and in-vivo. In-vivo segment is projected to experience around 22% growth throughout the analysis timeframe owing to various advantages associated with it. In-vivo gene therapy involves direct delivery of therapeutic gene into the target cell and has shown effective results in treatment of cancer. The viral vectors that are delivered utilizing in-vivo gene therapy help in inhibiting the activity of tumor inducing genes and has also shown positive results during clinical trials. Aforementioned factors will elevate the segmental growth.

Get In-depth table of contents @ https://www.gminsights.com/toc/detail/cancer-gene-therapy-market

Products of cancer gene therapy include viral vectors and non-viral vectors. Viral vectors segment was valued over USD 310 million in 2018. Viral vectors are highly preferred during gene transfer process as they have showcased high transfection efficiency. Viral vectors possess safety profile as compared to other vectors. Moreover, viral vectors expresses the desired antigen in accurate conformation enhancing the immune system.

End-users of cancer gene therapy are biopharmaceutical companies, research institutes and others. Biopharmaceutical companies segment accounted for around 48% revenue share in 2018 and is expected to experience exceptional growth in the forthcoming years. Companies such as Novartis and Roche are developing cancer gene therapies that have high adoption of viral as well as non-viral vectors, thereby proving beneficial for the segmental growth. These companies also conduct clinical trials that raises the demand for vectors, hence fostering the segmental growth.

China cancer gene therapy market will experience over 26% CAGR throughout the forecast years. Significant country growth can be attributed to the rising awareness regarding the availability of advanced therapies for treating cancer. Furthermore, increasing government initiatives and funds motivate the researchers and scientists for carrying out extensive research activities associated with cancer gene therapy that will positively influence the country growth. Above mentioned factors coupled with increasing prevalence of cancer will further stimulate the industry growth.

Cancer gene therapy industry is dominated by few major players. Cancer gene therapy industry is still in the developing phase, therefore, players involved in thie market focus on integrating advanced technology to promote developments in the therapies. The players also implement certain strategic initiatives such as merger, acquisitions and product launches for acquiring competitive advantage. For instance, in 2013, Celgene and bluebird bio collaborated to introduce innovations in gene therapies. Such collaborations will provide both the companies to gain competitive advantage over others.

View original post here:
Cognizance into Cancer Gene Therapy Market and it's growth prospects - Cole of Duty

The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.

Now, hes a believer and a partner.

Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.

The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.

I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

The rest is here:
Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D - Endpoints News

Dublin, June 18, 2020 (GLOBE NEWSWIRE) -- The "Nucleic Acid Isolation and Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Precision Medicine), End User (Academic) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global nucleic acid isolation and purification market is projected to reach USD 4.8 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 8.9% during the forecast period.

The major factors driving the growth of the market include increasing R&D activities as well as technological advancements and increasing automation. However, the high cost of automated instruments is expected to hinder the growth of the market.

The instruments segment will grow at the highest rate during the forecast period.

On the basis of product, the nucleic acid isolation and purification market are segmented into kits, reagents, and instruments. In 2019, kits were the largest product segment in the market. Growth in this market can be attributed to the continuous focus of key market players on developing and launching new and advanced kits. However, the instruments segment is expected to grow at the highest rate during the forecast period.

By type, the plasmid DNA isolation and purification segment accounted for the largest share of the nucleic acid isolation and purification market in 2019.

On the basis of type, the global nucleic acid isolation and purification market are segmented into plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. The plasmid DNA isolation segment accounted for the largest share of the nucleic acid isolation and purification market in 2019. The large share of this market segment can be attributed to the wide use of purified plasmid DNA in a variety of downstream applications, such as PCR, sequencing, expression of proteins, gene therapy, and transfection.

The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020-2025).

North America accounted for the largest share of the nucleic acid isolation and purification market in 2019. Significant R&D spending in biotechnology and pharmaceutical companies, the large size of the biotechnology industry, technological advancements, and government support in the region are the key factors driving the growth of the nucleic acid isolation and purification market in North America. On the other hand, the Asia Pacific is projected to register the highest growth during the forecast period. This large share can be attributed to factors such as the increasing number of genomic projects and increasing R&D investments by pharmaceutical & biotechnology companies in this region.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Nucleic Acid Isolation and Purification Market Overview 4.2 North America: Nucleic Acid Isolation and Purification Market, by Product (2019) 4.3 Geographical Snapshot of the Nucleic Acid Isolation and Purification Market

5 Market Overview 5.1 Market Dynamics 5.1.1 Drivers 5.1.1.1 Increasing R&D Activities 5.1.1.2 Technological Advancements and Increasing Automation 5.1.2 Restraints 5.1.2.1 High Cost of Automated Instruments 5.1.3 Opportunities 5.1.3.1 High Scope of Growth in Emerging Economies 5.1.3.2 Improving Regulatory and Reimbursement Scenario 5.1.3.3 Molecular Diagnostics and Personalized Medicine 5.1.4 Trends 5.1.4.1 Impact of the Covid-19 Pandemic 5.1.4.2 Increase in Government Funding

6 Nucleic Acid Isolation and Purification Market, by Product 6.1 Introduction 6.2 Kits 6.2.1 Kits Were the Largest Product Segment in the Market in 2019 6.3 Reagents 6.3.1 Reagents Segment to Grow at a Steady Rate During The Forecast Period 6.4 Instruments 6.4.1 Automated Instruments Enable a Faster, Cleaner, and More Consistent Nucleic Acid Extraction Process

7 Nucleic Acid Isolation and Purification Market, by Method 7.1 Introduction 7.2 Column-Based Isolation and Purification 7.2.1 Column-Based Isolation and Purification Was the Largest Segment in the Market in 2019 7.3 Magnetic Bead-Based Isolation and Purification 7.3.1 Magnetic Bead-Based Isolation and Purification Segment to Register the Highest CAGR During the Forecast Period 7.4 Reagent-Based Isolation and Purification 7.4.1 Reagent-Based Isolation and Purification Segment to Register Steady Growth During the Forecast Period 7.5 Other Isolation and Purification Methods

Story continues

8 Nucleic Acid Isolation and Purification Market, by Type 8.1 Introduction 8.2 Plasmid Dna Isolation and Purification 8.2.1 Plasmid Dna Isolation and Purification Accounted for the Largest Share of the Market 8.3 Total Rna Isolation and Purification 8.3.1 Total Rna Isolation and Purification Segment to Register Steady Growth 8.4 Genomic Dna Isolation and Purification 8.4.1 Genomic Dna Isolation is the First Step in Genetic-Based Tests 8.5 Messenger Rna Isolation and Purification 8.5.1 Messenger Rna Isolation and Purification is Mainly Used in the Study of Gene Expression and Transcriptomics 8.6 Circulating Nucleic Acid Isolation and Purification 8.6.1 Clinical Applications to Drive the Market for Circulating Nucleic Acid Isolation and Purification 8.7 Microrna Isolation and Purification 8.7.1 Microrna Kits Provide Rapid Isolation and Purification of Rna Molecules from Samples 8.8 Pcr Cleanup 8.8.1 Time-Consuming Laboratory Procedures to Limit the Growth of this Market During the Forecast Period 8.9 Other Nucleic Acid Isolation and Purification Types

9 Nucleic Acid Isolation and Purification Market, by Application 9.1 Introduction 9.2 Diagnostics 9.2.1 Diagnostic Applications Form the Largest and Fastest-Growing Segment in the Market 9.3 Drug Discovery & Development 9.3.1 Ngs Benefits Drug Discovery Applications in Various Therapeutic Areas 9.4 Personalized Medicine 9.4.1 Rising Incidence of Cancer and Increasing Research and Funding to Drive the Market for this Segment 9.5 Agriculture & Animal Research 9.5.1 Favorable Funding Scenario to Support Market Growth 9.6 Other Applications

10 Nucleic Acid Isolation and Purification Market, by End-user 10.1 Introduction 10.2 Hospitals & Diagnostic Centers 10.2.1 Availability of Genetic Tests and Rising Focus on Personalized Medicine in Hospitals to Drive Market Growth 10.3 Academic & Government Research Institutes 10.3.1 Increase in Research Intensity to Drive the Usage of Nucleic Acid Isolation and Purification Systems 10.4 Pharmaceutical & Biotechnology Companies 10.4.1 Increasing Number of Research Projects in Genomics and Related Areas is Expected to Drive the Market 10.5 Contract Research Organizations 10.5.1 Contract Research Organizations Are Expected to Register Steady Growth During the Forecast Period 10.6 Other End-users

11 Nucleic Acid Isolation and Purification Market, by Region 11.1 Introduction11.2 North America11.2.1 US11.2.1.1 Government and Private Funding to Support Market Growth in the Us11.2.2 Canada11.2.2.1 Demand for Nucleic Acid Isolation and Purification in Canada is Increasing Primarily Due to Growing Investments in Genomics11.3 Europe11.3.1 Germany11.3.1.1 Germany is the Largest Market for Nucleic Acid Isolation and Purification in Europe11.3.2 UK11.3.2.1 Government Support for Research in the Form of Investments, Funds, and Grants to Support Market Growth11.3.3 France 11.3.3.1 High Cancer Burden in France to Drive Market Growth 11.3.4 Roe 11.4 Asia-Pacific 11.4.1 China 11.4.1.1 China to Register the Highest Growth in the Nucleic Acid Isolation and Purification Market in APAC 11.4.2 Japan 11.4.2.1 Japan to Register Steady Growth During the Forecast Period 11.4.3 India 11.4.3.1 Strong Growth Trends in the Pharmaceutical & Biotechnology Industries to Drive the Market in India 11.4.4 Roapac 11.5 Rest of the World 11.5.1 Latin America 11.5.1.1 to Prevent Cancer Mortality, the Brazilian Government Recommends Screening Programs for Breast and Prostate Cancer 11.5.2 Middle East & Africa 11.5.2.1 Lack of Infrastructure for Research to Hamper the Growth of the Naip Market in the Middle East & Africa

12 Competitive Landscape 12.1 Introduction 12.2 Market Evaluation Framework 12.3 Revenue Analysis of Top Market Players 12.4 Competitive Scenario 12.4.1 Collaborations & Agreements 12.4.2 Product Launches & Approvals 12.4.3 Acquisitions 12.4.4 Expansions

13 Company Evaluation Matrix and Company Profiles 13.1 Company Evaluation Matrix 13.1.1 Market Share Analysis 13.2 Competitive Leadership Mapping (Overall Market) (2019) 13.2.1 Stars13.2.2 Emerging Leaders 13.2.3 Pervasive Players 13.2.4 Emerging Companies

14 Company Profiles 14.1 Qiagen N.V. 14.2 Thermo Fisher Scientific 14.3 F. Hoffman-La Roche AG 14.4 Promega Corporation 14.5 Agilent Technologies 14.6 Bio-Rad Laboratories 14.7 Danaher Corporation 14.8 GE Healthcare 14.9 Illumina 14.10 Merck Kgaa 14.11 Takara Bio, Inc. 14.12 New England Biolabs 14.13 Zymo Research 14.14 Norgen Biotek 14.15 Omega Bio-Tek, Inc. 14.16 Other Companies 14.16.1 Genaxxon Bioscience GmbH 14.16.2 3B Blackbio Biotech India Ltd. 14.16.3 Invitek Molecular GmbH 14.16.4 Biovision 14.16.5 Analytik Jena AG

15 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/abjwtq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:
Global Nucleic Acid Isolation and Purification Market (2020 to 2025) - High Scope of Growth in Emerging Economies - Yahoo Finance UK

Dublin, June 15, 2020 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking2.1. Introduction2.2. Gene therapy partnering over the years2.3. Most active Gene therapy dealmakers2.4. Gene therapy partnering by deal type2.5. Gene therapy partnering by therapy area2.6. Deal terms for Gene therapy partnering

Chapter 3 - Leading Gene therapy deals3.1. Introduction3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers4.1. Introduction4.2. Most active Gene therapy dealmakers4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

A selection of the companies mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/6xcnxy

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the rest here:
Gene Therapy Global Partnering Terms and Agreements Directory of Deals by the World's Leading Healthcare Companies from 2014-2020 - GlobeNewswire

Latest Gene Therapy Market report evaluates the impact of Covid-19 the industry, involving potential opportunity and challenges, drivers and risks and market growth forecast based on different scenario. Global Gene Therapy industry Market Report is a professional and in-depth research report on the worlds major regional market.

This Gene Therapy Market report will help the business leaders to detail better field-tested strategies and settle on educated choices to improved benefit

Get Exclusive Sample Report on Gene Therapy Market is available at https://inforgrowth.com/sample-request/6405074/gene-therapy-market

Top Players Listed in the Gene Therapy Market Report areBluebird Bio, Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical Inc., Advantagene.

Gene Therapymarket report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market Segmentations: Global Gene Therapy market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into Ex vivo, In Vivo.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Cancer, Monogenic, Infectious disease, Cardiovascular disease, Other.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6405074/gene-therapy-market

The report introduces Gene Therapy basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Gene Therapy Market for the coming few years have also been included in the report.

In the end, Gene Therapyreport provides details of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market for forecasting, regional demand, and supply factor, investment, market dynamics including technical scenario, consumer behavior, and end-use industry trends and dynamics, capacity, spending were taken into consideration.

Important Key questions answered in Gene Therapymarket report:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6405074/gene-therapy-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to read the rest:
Gene Therapy Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Bluebird Bio, Sangamo, Spark Therapeutics, Dimension...

INTRODUCTION Biologics represent one of the fastest growing classes of therapeutic molecules in modern healthcare. As per an article published in January 2020, the annual global market of biologics is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals.

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" - https://www.reportlinker.com/p05483804/?utm_source=GNW , Considering the necessity to bypass gastric metabolism, biologics are mostly designed for administration via parenteral routes. In fact, majority of such therapies are formulated for intravenous delivery and are usually administered in a clinical setting (hospitals / infusion centers). However, this scenario is cost intensive and is known to be associated with medication adherence related concerns. In this context, the subcutaneous route of drug delivery offers a number of benefits, including self-medication and life cycle management options. Although the pharmacokinetic profiles of intravenous and subcutaneous formulations are different, studies have demonstrated that the latter formulations are preferred by end users (patients and healthcare providers), offering substantial cost saving opportunities.

Presently, the subcutaneous delivery option is being investigated for a number of clinical candidates across different phases of development. Moreover, several approved therapeutic products, which are currently available in intravenous dosage forms, are also being reformulated and evaluated for subcutaneous administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been shown to result in highly viscous formulations when reformulated for subcutaneous delivery. In order to address this particular challenge, many companies have developed / are developing a number of novel technology platforms to facilitate the delivery of viscous drug formulations. Similar innovations are gradually facilitating a shift to subcutaneous delivery, primarily driven by the demand for self-administrable therapeutics. In fact, there are several self-medication solutions, equipped with a variety of user-friendly features, available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed high adoption, enabled substantial reductions in healthcare expenses (incurred by patients), and improved therapy adherence. In this regard, the rising incidence of chronic clinical conditions (which are characterized by the need for frequent medication) and the ongoing efforts of therapy / device developers engaged in this field, are anticipated to drive the growth of the subcutaneous biologics market in the coming years.

SCOPE OF THE REPORTThe Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following: A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route, along with information on approval year, phase of development, type of pharmacological molecule, target therapeutic area, dosing frequency, available dosage forms and key players. A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable). An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s). An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. Also, the study includes a detailed benchmark analysis of the technology developers based in North America and Europe, highlighting the primary advantage(s) offered by their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration. Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook. An analysis of collaborations and partnership agreements inked by the subcutaneous formulation technology developers since 2011; it includes details of deals that were / are focused on subcutaneous formulation technologies, which were analyzed on the basis of year of agreement, type of agreement, and upfront and milestone payments. An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows: Large volume wearable injectors: Stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force). Autoinjectors: Usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual). Pen injectors: Usability (disposable and reusable), volume / storage capacity (in mL), and type of dose (fixed dose and variable dose). Needle-free injection systems: Stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others). Drug reconstitution systems: Usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others). Prefilled syringes: Barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL). Implants: Stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. A comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information. A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industrys evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential of the subcutaneous biologics, technologies and drug delivery systems market. Based on historical trends and sales related information for subcutaneous biologic drugs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] phase of development (approved, preregistration & phase III and phase II & phase II/III)), [B] type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), [C] target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors and drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences) Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies) Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals) David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices) Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio) Poonam R Velagaleti (Co-Founder, i-novion) Michael Hooven (Chief Executive Officer, Enable Injections) Frederic Ors (Chief Executive Officer, Immunovaccine Technologies) Patrick Anquetil (Chief Executive Officer, Portal Instruments) Menachem Zucker (Vice President and Chief Scientist, Elcam Medical) Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) David Heuz (Communication Leader, MedinCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market over the next decade, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the subcutaneous biologics, technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction to the various types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecule structure, immunogenicity and stability. The chapter also highlights different types of biologically derived products that are currently being developed by various stakeholders in this industry. It further discusses the challenges associated with the parenteral route of drug delivery, specifically, those related to the traditional intravenous (infusion) route. Further, the chapter features a discussion on the different routes of administration, specifically focusing on the subcutaneous route, highlighting its advantages and associated limitations.

Chapter 4 includes information on over 450 subcutaneous biologic drug candidates that are currently approved / being developed. It features a comprehensive analysis of marketed and clinical-stage biologics based on the approval year, phase of development type of pharmacological molecule, target therapeutic area, dosing frequency, available dosage forms and key players.

Chapter 5 is a collection of case studies on the leading subcutaneous biologics, in terms of the annual global sales. Each case study includes drug / therapy specifications, their respective mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).

Chapter 6 provides a list of subcutaneous formulation technologies that are currently available / being developed by various firms in this domain. The chapter highlights key features of each technology and provides information on their developers. It also features an analysis based on the type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).

Chapter 7 features a three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength (number of drugs developed using a particular technology), supplier power (number of years of experience and company size) of the developer and primary advantages offered by their respective technologies. It also includes a benchmark analysis of technology developers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technologies, applicability to other types of pharmacological molecules, and other possible routes of drug administration

Chapter 8 includes elaborate profiles of key technology developers, featuring overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships related to the subcutaneous formulation technologies, which have been inked amongst players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others) that have been adopted by the stakeholders in this domain, since 2011. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants. It includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable injectors, by stage of development (commercialized and under development), type of device (infusion pump and patch pump), type of dose administered (continuous and bolus), volume / storage capacity (in mL), mode of injection (needle, needle / cannula and needle / catheter) and mechanism of action (driving force), [B] autoinjectors, by usability (disposable and reusable), type of primary container (syringe, cartridge and others), volume / storage capacity (in mL), type of dose (fixed dose and variable dose) and actuation mechanism (automatic, semi-automatic and manual), [C] pen-injectors, by usability (disposable and reusable), volume / storage capacity (in mL), and type of dose (fixed dose and variable dose), [D] needle-free injection systems, by stage of development (commercialized and under development), volume / storage capacity (in mL), usability (disposable and reusable), and actuation mechanism (spring-based, gas-powered and others), [E] drug reconstitution systems, by usability (disposable and reusable), device type (dual chambered systems and other novel systems) and type of drug container (cartridge, vials and others), [F] prefilled syringes, by barrel fabrication material (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and volume / storage capacity (in mL), and [G] implants, by stage of development (commercialized and under development), target therapeutic area, implant material (silicone, titanium, polymers and others) and treatment duration. As large volume wearable injectors, pre-filled syringes, needle-free injectors and autoinjectors represent the most novel and advanced types of devices, we have also provided a comprehensive product competitiveness analysis of these products taking into consideration the supplier power (based on size of employee base) and product specifications.

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industrys evolution, under a comprehensive SWOT framework; it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

Chapter 12 presents an informed estimate of the current and future opportunity in the subcutaneous biologics, technologies and drug delivery systems market, highlighting the likely growth of the market till the year 2030. It also includes future sales projections of various subcutaneous biologic drug candidates that are currently being evaluated by different players. The chapter presents a detailed market segmentation on the basis of phase of development (approved, preregistration & phase III and phase II and phase II/III), type of pharmacological molecule (proteins, peptides (recombinant), monoclonal antibodies, other antibody based products, cell / gene therapies and vaccines), target therapeutic areas (autoimmune disorders, metabolic disorders, blood disorders, bone disorders, oncological disorders, genetic disorders, neurological disorders, respiratory disorders and other disorders) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition to the market forecast for subcutaneous biologic drugs, we have also provided a 10-year forecast for subcutaneous delivery systems, covering the market for large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injectors, drug reconstitution systems. Further, we have also forecasted the revenues that subcutaneous formulation technology developers are likely to generate through licensing agreements; for this, we have provided a view on the likely upfront payments and milestone payments that will be generated from the deals related to the development of subcutaneous formulation of biologics.

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi ( Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Sr. Scientist Formulation, Xeris Pharmaceuticals), David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio), Poonam R Velagaleti (Co-Founder, i-novion), Michael Hooven (Chief Executive Officer, Enable Injections), Frederic Ors (Chief Executive Officer, Immunovaccine Technologies), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuz (Communication Leader, MedinCell).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05483804/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:
Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 - Yahoo Finance UK

Many age-related diseases such as liver fibrosis, atherosclerosis, diabetes and osteoarthritis have been partly attributed to cellular "senescence," a zombie-like state in which cellsstop proliferating but remain alive. Could CAR-T therapy, which involves genetically editing patients' own immunecells, treat those diseases by targeting senescent cells?

Researchers at Memorial Sloan Kettering Cancer Center haveset out to answer that question. They designed CAR-T cells that target a protein called urokinase plasminogen activator receptor (uPAR) on the surface of senescent cells. The CAR-T cells worked in mouse models of liver and lung cancers and liver fibrosis, the team reported in Nature.

Senescence is a double-edge sword, the studys co-corresponding author Scott Lowe explained in a statement. Cells in this state play an important role in wound healing and cancer deterrence. But if they linger for too long, they can cause chronic inflammation, which itself is a cause of many diseases.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

Clearing accumulated senescent cells has emerged is a new field in drug research called "senolytics." For example, Californias Unity Biotechnology is working on several senolytic drugs to treatage-related diseases, including one incollaboration with Chinas Ascentage Pharma to address a range of eye disorders.

But for CAR-T cells to work as senolytics, the Memorial Sloan Kettering researchers first needed to identify an antigen on senescent cells that the CAR (chimeric antigen receptor) couldtarget. The two CAR-T treatments on the market now, blood cancer drugs Kymriah from Novartis and Yescarta from Gilead Sciences, are directed at the antigen CD19 on cancer cells.

By screening molecules on the surface of cells in both mice and humans, the Memorial Sloan Kettering team found that uPAR was highly expressed on senescent cells but was mostly absent in normal tissue.

After designinguPAR-specific CAR-T cells, Lowe's team decided to test them in premalignant cells that typically undergo senescence. In mouse models of liver and lung cancer, the team found that the CAR-T cells successfully cleared these premalignant senescent cells. The treatment significantly prolonged survival in the lung cancer models.

In a mouse model of liver fibrosis marked by the accumulation of senescent cells in the liver, treatment with the uPAR-directedCAR-T cells significantly reduced liver scarring when compared to control animals. Blood levels of liver enzymes also dropped, indicating improved liver function. Similar results were observed in fibrosis induced by non-alcoholic steatohepatitis, or NASH, a liver condition many biopharma companies have tried to tackle but failed.

RELATED:Gene-edited T cells to treat diabetes inch closer to clinical trials

Several other research groups are investigating T-cell approaches for treating inflammatory diseases. Scientists at the University of Pennsylvania developed chimeric "autoantigen" receptor (CAAR) T cells that target rogue antibodies against the muscle-specific kinase to treat myasthenia gravis. A team at the University of Tennessee has investigated a CAR-T treatment that targets the harmful B cells behind lupus.

Recently, scientists from the Seattle Childrens Research Institute and the Benaroya Research Institute transformed CD4 T cells into cells with immunosuppressive properties with the goal of controlling the autoimmune response in Type 1 diabetes.

The Memorial Sloan Kettering team is hopeful their uPAR-directed senolytic CAR-T cells hold potential for treating several senescence-related diseases associated with aging. They're now planning to test the therapy in atherosclerosis, diabetes and osteoarthritis.

Read more:
Treating age-related diseases with a CAR-T that targets 'senescent' cells - FierceBiotech

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Global Genetic Modification Therapies market sizes from 2015 to 2024, along with CAGR for 2018-2024Market size comparison for 2017 vs 2024, with actual data for 2017, estimates for 2018 and forecast from 2019 to 2024Global Genetic Modification Therapies market trends, covering comprehensive range of consumer trends & manufacturer trendsValue chain analysis covering participants from raw material suppliers to the downstream buyer in the global Genetic Modification Therapies marketMajor market opportunities and challenges in forecast timeframe to be focusedCompetitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic managementComprehensive company profiles of the key industry players

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Gain detailed insights on the Genetic Modification Therapies industry trendsFind complete analysis on the market statusIdentify the Genetic Modification Therapies market opportunities and growth segmentsAnalyse competitive dynamics by evaluating business segments & product portfoliosFacilitate strategy planning and industry dynamics to enhance decision making

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

IntroductionResearch MethodologyExecutive SummaryMarket Overview4.1 Introduction4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.2.4 Challenges4.2 Porters Five Force AnalysisGenetic Modification Therapies Market, By Platform TechnologyGenetic Modification Therapies Market, By Delivery TechnologiesGenetic Modification Therapies Market, By End-User IndustryGenetic Modification Therapies Market, By DiseaseGenetic Modification Therapies Market, By GeographyCompetitive InsightsCompany Profiles11.1 4D Molecular Therapeutics11.1.1 Company Overview11.1.2 Product/Service Landscape11.1.3 Financial Overview11.1.4 Recent Developments11.2 Abeona Therapeutics11.2.1 Company Overview11.2.2 Product/Service Landscape11.2.3 Financial Overview11.2.4 Recent Developments11.3 Beam Therapeutics,11.3.1 Company Overview11.3.2 Product/Service Landscape11.3.3 Financial Overview11.3.4 Recent Developments11.4 Casebia Therapeutics,11.4.1 Company Overview11.4.2 Product/Service Landscape11.4.3 Financial Overview11.4.4 Recent Developments11.5 Editas Medicine,11.5.1 Company Overview11.5.2 Product/Service Landscape11.5.3 Financial Overview11.5.4 Recent Developments11.6 Fate Therapeutics,11.6.1 Company Overview11.6.2 Product/Service Landscape11.6.3 Financial Overview11.6.4 Recent Developments11.7 GE Healthcare,11.7.1 Company Overview11.7.2 Product/Service Landscape11.7.3 Financial Overview11.7.4 Recent Developments11.8 Hitachi Chemical Advanced Therapeutics,11.8.1 Company Overview11.8.2 Product/Service Landscape11.8.3 Financial Overview11.8.4 Recent Developments11.9 Immunocore,11.9.1 Company Overview11.9.2 Product/Service Landscape11.9.3 Financial Overview11.9.4 Recent Developments11.10 Jivana Biotechnology,11.10.1 Company Overview11.10.2 Product/Service Landscape11.10.3 Financial Overview11.10.4 Recent Developments

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read the rest here:
Genetic Modification Therapies Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole...

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Membrane Chromatography Market by Product, Technique, Operation Mode, End User - Global Forecast to 2025" - https://www.reportlinker.com/p05339881/?utm_source=GNW 5% during the forecast period. The major factors driving the growth of this market are the benefits offered by membrane chromatography over conventional chromatography methods, increasing biopharmaceutical R&D, and increasing regulatory scrutiny on the cleaning validation of downstream purification processes.

The consumables segment commanded the largest share of the market in 2019.On the basis of product, the membrane chromatography market is segmented into consumables and accessories.The capsules, cassettes, and cartridges segment accounted for the largest share of the membrane chromatography consumables market in 2019.

The large share of this segment is primarily attributed to the increasing use of capsules and cartridges for purification applications in biomanufacturing, lab-scale production, and process development.

The affinity membrane chromatography segment is expected to register the highest growth in the global membrane adsorbers market during the forecast period.On the basis of technique, the membrane adsorbers market is segmented into ion exchange membrane chromatography, affinity membrane chromatography, and hydrophobic interaction membrane chromatography.The affinity membrane chromatography segment is estimated to grow at the highest CAGR during the forecast period.

The increasing use of protein A chromatography for antibody purification and immobilized metal affinity membrane chromatography for the purification of proteins are supporting the growth of this segment.

The pharmaceutical and biopharmaceutical companies segment commanded the largest share of the membrane chromatography market in 2019.Based on end user, the membrane chromatography market is segmented into pharmaceutical and biopharmaceutical companies, CROs, and academic and research institutes.In 2019, the pharmaceutical and biopharmaceutical companies segment accounted for the largest market share.

The large share of this segment is attributed to the increased R&D in pharmaceutical and biopharmaceutical companies and increased production of biologics.

The bind-elute segment is projected to register the highest growth in the global membrane adsorbers market during the forecast period.The bind-elute membrane chromatography segment is estimated to grow at the highest CAGR during the forecast period. The increasing demand for viruses in the production of attenuated vaccines and gene therapy and the development of high-performance bind-elute membrane chromatography solutions (with a higher binding capacity to capture larger targets such as adenovirus and lentivirus and virus-like particles) are the key factors driving the growth of this segment.

The Asia Pacific market is projected to register the highest growth in the global membrane chromatography market during the forecast period.The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The growing biopharmaceutical industry, significant investments by key market players, increasing government support, and developing R&D infrastructure are the key factors driving the growth of this segment.

In-depth interviews were conducted with chief executive officers (CEOs), marketing directors, other directors, and executives from various key organizations operating in the membrane chromatography market. By Respondent Type: Supply Side (70%) and Demand Side (30%) By Designation: Managers (55%), CXOs (20%), and Executives (25%) By Region: North America (50%), Europe (20%), APAC (20%), and the RoW (10%)

The membrane chromatography market comprises major players such as Sartorius AG (Germany), Danaher Corporation (US), Merck Millipore (Germany), Thermo Fisher Scientific Inc. (US), and 3M Company (US). The study includes an in-depth competitive analysis of these key players in the membrane chromatography market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:The market study covers the membrane chromatography market across various segments.It aims at estimating the market size and the growth potential of this market across different segments based on product, technique, end user, and region.

The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall membrane chromatography market and its subsegments.This report will help stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.

The report will also help stakeholders to understand the pulse of the market and provide information on the key market drivers, restraints, opportunities, and challenges.Read the full report: https://www.reportlinker.com/p05339881/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the article here:
The membrane chromatography market is estimated to grow from USD 198 million in 2020 to USD 408 million by 2025, at a CAGR of 15.5% - GlobeNewswire

The research reports on Emerging Gene Therapies Market report gives detailed overview of factors that affect global business scope. Emerging Gene Therapies Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Emerging Gene Therapies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1854862

Top Company Profile Analysis in this Report

AmgenGilead SciencesNovartisSanofiGlaxoSmithKlinePfizer

and more

Emerging Gene Therapies Market Report provides a comprehensive overview of the emerging gene therapy market. The report discusses gene therapy and the technology behind gene editing, outlining the advantages, limitations and current evidence for the platforms under development. The report discusses relevant clinical studies targeting specific therapeutic indications and highlights examples of current challenges within the field, with a focus on therapies that target the eye, liver, and blood.

Additionally, the report provides a background to the CRISPR patent litigation, a key factor within the gene editing company landscape. It provides profiles of six companies developing gene editing platforms, considers the gene therapy interests of the main pharmaceutical companies, and discusses current regulatory trends in the development of gene therapies.

Emerging Gene Therapies Market Report explores how emerging gene editing products will compete with established products, their relative competitive strengths, and upcoming value inflection points within the field.

Scope of this Report- What are the key emerging products within the gene therapy landscape? Which companies have the strongest pipeline of innovative products? How will gene editing disrupt existing gene therapy products? What are the regulatory trends for emerging gene therapies? What are the interests of pharmaceutical companies within the field?

Reasons to buy this Report- Achieve an up-to-date understanding of the area, with a comprehensive reference of key products within the gene therapy landscape, compared across technology-specific relevant characteristics such as editing mechanism and delivery vector. Conduct competitive analysis using indication-specific, side-by-side comparisons of the latest data for key gene therapy products in the strategically relevant areas of eye, blood, and liver. Conduct strategic analysis using an overview of gene therapy specific considerations for evaluating and developing gene therapy products the CRISPR patent space, emerging regulatory trends, innovation leaders and the interests of pharma in gene therapy.

Single User License: US $ 2995

Get FLAT 20% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=1854862

Table of Contents in this Report-1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Introduction 102.1 Gene Therapy Definitions 102.2 Report Coverage the Emerging Gene Therapy Pipeline 112.3 History of Gene Therapy 122.4 Limitations of Gene Transfer 132.5 The Development of Targeted Gene Editing 132.6 Overview of Gene Editing Platforms 132.6.1 Zinc Fingers (1996) 132.6.2 Transcription Activator-Like Effectors (2011) 142.6.3 The CRISPR/Cas System (2013) 152.6.4 Effectors for Targeting Domains 192.6.5 Comparison of Gene Editing Systems 192.6.6 Summary of Gene Editing Systems 192.7 Overview of In Vivo Gene Therapy 212.7.1 Editing is Dependent on Cell Type, Stage, and Repair Pathway 212.7.2 Delivery 212.7.3 Emerging Safety Concerns with Editing Platforms 242.7.4 Editing Products are Reliant on the Target Cells Cycle Stage and DNA Repair Machinery 272.7.5 Advantages of Gene Editing over Gene Transfer 282.7.6 Integration into Safe Harbor Sites 282.7.7 The Increasing Complexity of Gene Therapy 302.7.8 Summary of In Vivo Gene Therapy 313 Gene Therapy Near Term Product Pipeline 333.1 Leber Congenital Amaurosis 333.1.1 Unmet Need 333.1.2 Molecular Genetics 333.1.3 Luxturna (Voretigene neparvovec) 333.1.4 Editas Medicine: EDIT-101 353.1.5 Trial Design 363.1.6 EDIT-101 and Off-Target Effects 373.1.7 The Potential Advantage of EDIT-101 is the Longevity of its Therapeutic Effect 373.1.8 Summary LCA 383.2 Choroideremia 383.3 Hurler Syndrome (MPS I) 393.3.1 Key Clinical Studies 403.3.2 Regenex: RGX-111 403.3.3 Sangamo Therapeutics: SB-318 403.4 Hunter Syndrome (MPS II) 413.4.1 Unmet Need 413.4.2 Sangamo Therapeutics: SB-913 413.4.3 Immusoft Corporation: Cell Therapy 433.5 Sanfilippo Syndrome (MPS III) 433.5.1 Lysogene: LYS-SAF302 433.6 Summary MPS Disorders 443.7 Hemophilia 443.7.1 Hemophilia A 463.7.2 Summary Hemophilia A 503.7.3 Hemophilia B 513.7.4 Summary Hemophilia B 533.8 Hemoglobinopathies 543.8.1 Beta Thalassemia: Unmet Need 543.8.2 Beta Thalassemia: Molecular Genetics 553.8.3 Sickle Cell Disease: Unmet Need 563.8.4 Sickle Cell Disease: Molecular Genetics 563.9 Cellular Therapies for Hemoglobinopathies 573.9.1 Blue Bird Bio: BB-305 (LentiGlobin) 573.9.2 Sangamo: ST-400 603.9.3 CRISPR Therapeutics: CTX-001 613.9.4 Summary: Cellular Therapies for Hemoglobinopathies 623.10 Duchenne Muscular Dystrophy 633.10.1 Unmet Need 633.10.2 Molecular Genetics 633.10.3 ExonDys 51 Sarepta Therapeutics 643.10.4 Solid BioSciences: SGT-001 663.10.5 Exonics Therapeutics: CRISPR Approach 673.10.6 Summary Duchenne Muscular Dystrophy 684 Competitive Landscape 694.1 Regulatory Considerations for Developing Gene Therapy Products 694.1.1 Product Characteristics 694.1.2 Clinical Study Design for Gene Therapy Products 694.1.3 Disease specific guidance 704.1.4 Reimbursement and Payment 714.1.5 Summary Regulatory Considerations 724.2 Intellectual Property CRISPR/Cas 724.2.1 Licensing, Exploitation, and MPEG Pool 744.3 Company Analysis: Gene Editing Companies 754.3.1 Sangamo Therapeutics 754.3.2 CRISPR Therapeutics 794.3.3 Casebia Therapeutics 814.3.4 Editas Medicine 824.3.5 Intellia Therapeutics 844.3.6 Homology Medicines 864.4 Company Analysis: Pharma 874.4.1 Amgen 874.4.2 Gilead Sciences 874.4.3 Novartis 874.4.4 Sanofi 884.4.5 GlaxoSmithKline 884.4.6 Pfizer 885 Appendix 895.1 References 895.2 Report Methodology 98

and more

Read more:
2020 Emerging Gene Therapies Market Report- Trends within the Technological, Clinical, Regulatory and Competitive Landscape - 3rd Watch News

DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking

2.1. Introduction

2.2. Gene therapy partnering over the years

2.3. Most active Gene therapy dealmakers

2.4. Gene therapy partnering by deal type

2.5. Gene therapy partnering by therapy area

2.6. Deal terms for Gene therapy partnering

Chapter 3 - Leading Gene therapy deals

3.1. Introduction

3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers

4.1. Introduction

4.2. Most active Gene therapy dealmakers

4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

5.1. Introduction

5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

A selection of the companies mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/mam3lf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Original post:
Global Gene Therapy Partnering Terms and Agreements Directory 2014-2020 - ResearchAndMarkets.com - Business Wire

INTRODUCTION Over the last few years, the exponential growth in the pipeline of nucleic acid based therapies has led to the escalating interest of pharmaceutical industry in this domain.

New York, June 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Non-Viral Transfection Reagents and Systems Market, 2020-2030" - https://www.reportlinker.com/p05915358/?utm_source=GNW Presently, more than 2,000 trials evaluating different types of gene therapies are underway. Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022. In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing. Although, viral vectors have shown significant success in R&D, their applications are limited due to immunogenicity and toxicity related concerns, high development costs and the limitation on amount of genomic material that they can carry. Excessively high price tags associated with viral-based therapies, such as Zolgensma (USD 2.1 million) and Luxtruna (USD 850,000), have led to several reimbursement challenges, thereby decreasing patient access. Owing to the aforementioned concerns related to viral vectors, therapy developers are evaluating a variety of non-viral methods of gene delivery.

In the present scenario, non-viral transfection systems are not yet widely used in therapy development and clinical studies, primarily due to their relatively low efficiency compared to viruses. The applications of these methods are largely restricted to fundamental research, including protein and gene expression, and cell line development. However, there are a number of companies that have developed proprietary technologies and products to facilitate physical (electroporation, gene gun, microinjection and sonoporation), chemical (transfection reagents) and other non-viral methods of transfection (transposon based systems, piggyBac and magnetofection). We believe that, as the demand for advanced therapy medicinal products, which require genetic engineering, the opportunity for non-viral transfection system developers is also likely to grow.

SCOPE OF THE REPORTThe Non-Viral Transfection Reagents and Systems Market, 2020-2030 report features an extensive study of the various systems and technologies available for non-viral transfection, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features: A detailed assessment of the competitive landscape of various types of non-viral transfection systems, including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location. An insightful 2X2 representation, highlighting the competitiveness analysis of non-viral transfection system developers captured in our database, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered). An analysis highlighting potential strategic partners segregated based on likelihood of entering into collaboration with non-viral transfection system developers. The analysis takes into consideration multiple relevant parameters, such as type of therapy, pipeline strength, pipeline maturity, type of vector and company size. An analysis of the big pharma players engaged in this domain, featuring a heat map based on parameters, such as type of initiative, type of therapy and target therapeutic area. An analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population. An in-depth analysis of close to 14,000 patents related to non-viral transfection systems that have been filed / granted since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis. A detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as annual number of transfections, cost per transfection, share of non-viral systems within the transfections market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2020-2030. The chapter features the likely distribution of the future opportunity across [A] non-viral transfection systems (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the markets evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names): George Eastwood (Vice-President of Business Development, Kytopen) Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified..

RESEARCH METHODOLOGYThe research, analysis and insights presented in this report are backed by a deep understanding of insights gathered from both secondary and primary sources. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the non-viral transfection systems market in the mid to long term.

Chapter 3 provides an overview of transfection and its applications, such as advanced therapy medicinal product development, gene silencing, bioproduction of therapeutic protein and stem cell engineering. It highlights different methods of transfection (such as viral and non-viral), with a brief outline of various viral vectors (AAV, adenoviral, lentiviral, retroviral and others), chemical methods (lipoplexes, polyplexes, lipoplexes and others) and physical methods (electroporation, gene gun, sonoporation, magnetofection and others) used in transfection.

Chapter 4 provides an overview of various types of non-viral transfection systems including transfection reagents, electroporation-based transfection systems and other non-viral transfection systems, featuring product specific information, such as type of carrier used, type of molecule delivered, recommended cell type and price of the system (if available). Additionally, the chapter includes information on non-viral transfection system developers, including information on year of establishment, company size and geographical location.

Chapter 5 provides a detailed competitiveness analysis of the companies offering non-viral transfection systems, taking into consideration supplier power (based on company size) and service strength (based on strength of product portfolio, years of experience and type of molecule delivered).

Chapter 6 includes detailed profiles of prominent transfection reagent developers, electroporation-based transfection system developers and other non-viral delivery system developers, featuring a brief overview of the company, its financial information (if available), recent developments and an informed future outlook.

Chapter 7 features an insightful analysis, highlighting potential strategic partners, based on likelihood of entering into collaboration with non-viral transfection system developers, taking into account several parameters, such as type of therapy, pipeline strength, pipeline maturity, company size and type of vector.

Chapter 8 highlights the activity of top ten big pharma players in this domain, featuring a heat map based on parameters, such as such as type of initiative, type of therapy and target therapeutic area.

Chapter 9 provides an analysis of completed, ongoing and planned clinical studies related to non-viral transfection systems, featuring details on registration year, trial phase, trial status, type of sponsor, type of therapy, target therapeutic area, trial design, type of patient allocation model used, type of trial masking adopted, type of intervention, trial purpose, geographical location of trial and enrolled patient population.

Chapter 10 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to non-viral transfection systems, since 2017, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.

Chapter 11 presents a detailed publication analysis of more than 1,100 peer-reviewed, scientific articles that have been published since 2014, highlighting the key trends associated with these publications, across year of publication, focus area, type of molecule delivered, target therapeutic area, important cells and cell lines evaluated, leading players across different geographies and key journals (in terms of number of articles published in the given time period) within this domain.

Chapter 12 presents a detailed market forecast, highlighting the future potential of the non-viral transfection systems market till the year 2030. The chapter features the likely distribution of the opportunity across different [A] non-viral transfection methods (non-viral transfection reagents, electroporation-based transfection systems and other non-viral transfection systems), [B] end-users (academic and research institutions, pharmaceutical companies and other end-users), [C] area of application (clinical application and research application) and [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 13 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with George Eastwood (Vice-President of Business Development, Kytopen) and Claudia Andretta (Global Business Development Manager, Clinical, Polyplus-transfection).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05915358/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Excerpt from:
Non-Viral Transfection Reagents and Systems Market, 2020-2030 - Yahoo Finance

Click to Access Sample Pages @https://www.orianresearch.com/request-sample/722408Ethical concerns with the use of embryonic stem cell for r&d, lack of clear regulatory guideline are some of major factors which can hamper the growth of the market.

Rising Demand for Organ Transplantation and Strong Product Pipeline are some of the opportunitites in the forecast period.

Based on therapy the market is segmented into cell therapy, gene therapy, tissue engineering, immunotherapy. The cell-based products is expected to dominate the global Regenerative Medicine market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies are driving the growth of the cell therapy segment.

Based on application the market is segmented into, Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology

North America dominates the regenerative medicine market due to rapid technological advancements and high investment & funding to support development of regenerative medicine. Asia-Pacific is also expected to propel the regenerative medicine market, owing to factors, such as increasing accessibility to healthcare facilities in the region, and surging economic growth.

Some of the key players operating in this market includeOrganogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

Key Benefits of the Report:

* Global, Regional, Country, Therapy, and APPLICATION Market Size and Forecast from 2014-2025

* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Therapy& Application, and competitive landscape with qualitative and quantitative information and facts.

Global Regenerative Medicine Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/722408

Target Audience:

* Regenerative Medicine providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies.

The Report Covers Exhaustive Analysis on:

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Manufacturer,

* Therapy Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute.

Order a Copy of Global Regenerative Medicine Market Report @https://www.orianresearch.com/checkout/722408

TABLE OF CONTENT

1 Executive Summary

2 Methodology And Market Scope

3 Regenerative Medicine Market Industry Outlook

4 Regenerative Medicine Market By Product Type

5 Regenerative Medicine Market Application Type

6 Regenerative Medicine Market Regional

7 Competitive Landscape

End Of The Report

Disclaimer

Customization Service of the Report:Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Read the original:
COVID 19 Impact on REGENERATIVE MEDICINE MARKET 2020 GLOBAL INDUSTRY SIZE, ANALYSIS, FUTURE GROWTH, TYPES, END-USERS, KEY PLAYERS AND REGIONAL...

The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.

Now, hes a believer and a partner.

Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.

The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.

I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.

Unlock this article along with other benefits by subscribing to one of our paid plans.

SUBSCRIBE SIGN IN

Continue reading here:
A Bay Area upstart with legendary godfathers breaks cover, touting claims of a curative tech, unicorn status and a $300M plan to shoot for an approval...

Carbenicillin is categorized as a semisynthetic penicillin antibiotic which is widely employed in cell culture and molecular biology application due to its ability to inhibit cell wall synthesis by inactivating the transpeptidase present on the inner cell surface of the microbial cell wall.

Cell culture is representing the largest market share in the application segment for the carbenicillin market. Ergonomic features such as very high and improved stability in comparison to ampicillin render it to use in a concentration of 100 g/ml in the cell culture media for the selection of ampr transformed cells. Additionally, features such as high resistance to heat and low pH-induced degradation with respect to different time intervals in the accelerated stability testing studies increase its applicability in liquid culture growth. Molecular biology is going to record rampant market growth during the forecast period on account of the rising prevalence of pandemic infections and chronic diseases worldwide. Carbenicillin is widely used to regulate the bacterial growth in the plants thereby yielding low regeneration frequencies and it is also utilized as a gene selection antibiotic in plant molecular biology to utilize the CRISPR / CAS9 system.

Browse the fullreport Carbenicillin Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 2027 athttps://www.atlanticmarketresearch.com/carbenicillin-market

Biopharmaceutical companies are presently leading the end-user segment for the carbenicillin market. Severe adverse side effects associated with chemotherapy has resulted in the increasing demand for gene therapy and immunotherapy for the treatment of metastatic cancer owing to its enhanced therapeutic efficacy and safety. Significant increase in the research and development sector of the life sciences segment for the development of bioengineered molecules utilized in the treatment of rare hereditary diseases. Research academia is expected to register excellent market growth in the near future owing to the increasing funds provided by the government healthcare agencies for novel drug development to curb the mortality rate associated with infectious and chronic diseases across the globe.

North America is presently spearheading the geography segment for thecarbenicillin market. The existence of developed healthcare infrastructure and increasing public health awareness regarding the therapeutic application of biomolecules in the treatment of chronic diseases together steer the market growth in the region. The presence of major players such as Thermo Fisher Scientific, Santa Cruz Biotechnology, Inc., VWR International, LLC, Selleck Chemicals, etc. fortifies the carbenicillin market growth in the region. Europe is placed 2nd in the regional segment for the carbenicillin market. A supportive regulatory environment for the sale and distribution of carbenicillin in the life sciences industry segment provided by the European Medical Agency (EMA), further accentuates the market growth. The Asia Pacific is anticipated to be the fastest-growing regional segment for the carbenicillin market. Developing the life sciences industry and the emergence of local manufacturers together determine the carbenicillin market growth in the Asia Pacific region.

Pharmaceutical manufacturers actively engaged in the production of carbenicillin are Merck KGaA, Thermo Fisher Scientific., Corning, HiMedia Laboratories, VWR International, LLC, Gold Biotechnology, Inc., Selleck Chemicals, Santa Cruz Biotechnology, Inc., Canvax Biotech S.L., and CliniSciences.

Key Market Movements:

About Atlantic Market Research

AtlanticMarketResearch is thelargest provider of marketresearch and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:Mr. Trevor WilsonAtlantic Market Research911 Central Ave #268Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.comEmail: [emailprotected]

Here is the original post:
Global Carbenicillin Market Is Expected to Grow At A CAGR of 4.0% from 2020 to 2027 - Cole of Duty

LOS ANGELES, United States: QY Research has recently published a report, titled Global Viral Vector Manufacturing Market Size, Status and Forecast 2020-2026.The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Viral Vector Manufacturing market. It informs readers about key trends and opportunities in the global Viral Vector Manufacturing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Viral Vector Manufacturing market.

Key companies operating in the global Viral Vector Manufacturing market include BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, FUJIFILM Diosynth Biotechnologies, Lonza, Biovian, Thermo Fisher Scientific (Brammer Bio) Viral Vector Manufacturing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1531774/global-viral-vector-manufacturing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Viral Vector Manufacturing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Viral Vector Manufacturing Market Segment By Type:

, Adenoviral Vectors, Adeno-associated Viral Vectors, Retroviral Vectors, Lentiviral Vectors, Other Viral Vector Manufacturing

Global Viral Vector Manufacturing Market Segment By Application:

, Gene Therapy, Vaccinology

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Viral Vector Manufacturing market.

Key companies operating in the global Viral Vector Manufacturing market include BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, FUJIFILM Diosynth Biotechnologies, Lonza, Biovian, Thermo Fisher Scientific (Brammer Bio) Viral Vector Manufacturing

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1531774/global-viral-vector-manufacturing-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Viral Vector Manufacturing Revenue1.4 Market by Type1.4.1 Global Viral Vector Manufacturing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Adenoviral Vectors1.4.3 Adeno-associated Viral Vectors1.4.4 Retroviral Vectors1.4.5 Lentiviral Vectors1.4.6 Other1.5 Market by Application1.5.1 Global Viral Vector Manufacturing Market Share by Application: 2020 VS 20261.5.2 Gene Therapy1.5.3 Vaccinology1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Viral Vector Manufacturing Market Perspective (2015-2026)2.2 Global Viral Vector Manufacturing Growth Trends by Regions2.2.1 Viral Vector Manufacturing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Viral Vector Manufacturing Historic Market Share by Regions (2015-2020)2.2.3 Viral Vector Manufacturing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Viral Vector Manufacturing Market Growth Strategy2.3.6 Primary Interviews with Key Viral Vector Manufacturing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Viral Vector Manufacturing Players by Market Size3.1.1 Global Top Viral Vector Manufacturing Players by Revenue (2015-2020)3.1.2 Global Viral Vector Manufacturing Revenue Market Share by Players (2015-2020)3.1.3 Global Viral Vector Manufacturing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Viral Vector Manufacturing Market Concentration Ratio3.2.1 Global Viral Vector Manufacturing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Viral Vector Manufacturing Revenue in 20193.3 Viral Vector Manufacturing Key Players Head office and Area Served3.4 Key Players Viral Vector Manufacturing Product Solution and Service3.5 Date of Enter into Viral Vector Manufacturing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Viral Vector Manufacturing Historic Market Size by Type (2015-2020)4.2 Global Viral Vector Manufacturing Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Viral Vector Manufacturing Market Size by Application (2015-2020)5.2 Global Viral Vector Manufacturing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Viral Vector Manufacturing Market Size (2015-2020)6.2 Viral Vector Manufacturing Key Players in North America (2019-2020)6.3 North America Viral Vector Manufacturing Market Size by Type (2015-2020)6.4 North America Viral Vector Manufacturing Market Size by Application (2015-2020) 7 Europe7.1 Europe Viral Vector Manufacturing Market Size (2015-2020)7.2 Viral Vector Manufacturing Key Players in Europe (2019-2020)7.3 Europe Viral Vector Manufacturing Market Size by Type (2015-2020)7.4 Europe Viral Vector Manufacturing Market Size by Application (2015-2020) 8 China8.1 China Viral Vector Manufacturing Market Size (2015-2020)8.2 Viral Vector Manufacturing Key Players in China (2019-2020)8.3 China Viral Vector Manufacturing Market Size by Type (2015-2020)8.4 China Viral Vector Manufacturing Market Size by Application (2015-2020) 9 Japan9.1 Japan Viral Vector Manufacturing Market Size (2015-2020)9.2 Viral Vector Manufacturing Key Players in Japan (2019-2020)9.3 Japan Viral Vector Manufacturing Market Size by Type (2015-2020)9.4 Japan Viral Vector Manufacturing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Viral Vector Manufacturing Market Size (2015-2020)10.2 Viral Vector Manufacturing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Viral Vector Manufacturing Market Size by Type (2015-2020)10.4 Southeast Asia Viral Vector Manufacturing Market Size by Application (2015-2020) 11 India11.1 India Viral Vector Manufacturing Market Size (2015-2020)11.2 Viral Vector Manufacturing Key Players in India (2019-2020)11.3 India Viral Vector Manufacturing Market Size by Type (2015-2020)11.4 India Viral Vector Manufacturing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Viral Vector Manufacturing Market Size (2015-2020)12.2 Viral Vector Manufacturing Key Players in Central & South America (2019-2020)12.3 Central & South America Viral Vector Manufacturing Market Size by Type (2015-2020)12.4 Central & South America Viral Vector Manufacturing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 BioReliance13.1.1 BioReliance Company Details13.1.2 BioReliance Business Overview13.1.3 BioReliance Viral Vector Manufacturing Introduction13.1.4 BioReliance Revenue in Viral Vector Manufacturing Business (2015-2020))13.1.5 BioReliance Recent Development13.2 Cobra Biologics13.2.1 Cobra Biologics Company Details13.2.2 Cobra Biologics Business Overview13.2.3 Cobra Biologics Viral Vector Manufacturing Introduction13.2.4 Cobra Biologics Revenue in Viral Vector Manufacturing Business (2015-2020)13.2.5 Cobra Biologics Recent Development13.3 Oxford BioMedica13.3.1 Oxford BioMedica Company Details13.3.2 Oxford BioMedica Business Overview13.3.3 Oxford BioMedica Viral Vector Manufacturing Introduction13.3.4 Oxford BioMedica Revenue in Viral Vector Manufacturing Business (2015-2020)13.3.5 Oxford BioMedica Recent Development13.4 UniQure13.4.1 UniQure Company Details13.4.2 UniQure Business Overview13.4.3 UniQure Viral Vector Manufacturing Introduction13.4.4 UniQure Revenue in Viral Vector Manufacturing Business (2015-2020)13.4.5 UniQure Recent Development13.5 FinVector13.5.1 FinVector Company Details13.5.2 FinVector Business Overview13.5.3 FinVector Viral Vector Manufacturing Introduction13.5.4 FinVector Revenue in Viral Vector Manufacturing Business (2015-2020)13.5.5 FinVector Recent Development13.6 MolMed13.6.1 MolMed Company Details13.6.2 MolMed Business Overview13.6.3 MolMed Viral Vector Manufacturing Introduction13.6.4 MolMed Revenue in Viral Vector Manufacturing Business (2015-2020)13.6.5 MolMed Recent Development13.7 MassBiologics13.7.1 MassBiologics Company Details13.7.2 MassBiologics Business Overview13.7.3 MassBiologics Viral Vector Manufacturing Introduction13.7.4 MassBiologics Revenue in Viral Vector Manufacturing Business (2015-2020)13.7.5 MassBiologics Recent Development13.8 FUJIFILM Diosynth Biotechnologies13.8.1 FUJIFILM Diosynth Biotechnologies Company Details13.8.2 FUJIFILM Diosynth Biotechnologies Business Overview13.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing Introduction13.8.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing Business (2015-2020)13.8.5 FUJIFILM Diosynth Biotechnologies Recent Development13.9 Lonza13.9.1 Lonza Company Details13.9.2 Lonza Business Overview13.9.3 Lonza Viral Vector Manufacturing Introduction13.9.4 Lonza Revenue in Viral Vector Manufacturing Business (2015-2020)13.9.5 Lonza Recent Development13.10 Biovian13.10.1 Biovian Company Details13.10.2 Biovian Business Overview13.10.3 Biovian Viral Vector Manufacturing Introduction13.10.4 Biovian Revenue in Viral Vector Manufacturing Business (2015-2020)13.10.5 Biovian Recent Development13.11 Thermo Fisher Scientific (Brammer Bio)10.11.1 Thermo Fisher Scientific (Brammer Bio) Company Details10.11.2 Thermo Fisher Scientific (Brammer Bio) Business Overview10.11.3 Thermo Fisher Scientific (Brammer Bio) Viral Vector Manufacturing Introduction10.11.4 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vector Manufacturing Business (2015-2020)10.11.5 Thermo Fisher Scientific (Brammer Bio) Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:
Trending: Viral Vector Manufacturing Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026 - Cole...